How Does Parkinson’s Prevalence Differ by Ethnicity, What Percentage of Different Groups Are Affected, and How Do Genetic Versus Environmental Factors Contribute? 🌍🧠

This article is written by mr.hotsia, a long term traveler and storyteller who runs a YouTube travel channel followed by over a million followers. Over the years he has crossed borders and backroads throughout Thailand, Laos, Vietnam, Cambodia, Myanmar, India and many other Asian countries, sleeping in small guesthouses, village homes and roadside inns. Along the way he has listened to real life health stories from locals, watched how people actually live day to day, and collected simple lifestyle ideas that may help support better wellbeing in practical, realistic ways.

When people ask whether Parkinson’s disease affects all ethnic groups in the same way, the honest answer is no, but the picture is more tangled than a simple ranking chart. Some studies show higher measured prevalence in White populations, lower measured rates in Black populations, and intermediate rates in Hispanic or Asian groups. But researchers are increasingly cautious, because those observed differences can reflect not only true biology, but also who gets diagnosed, who reaches a specialist, who is counted in the data, and whose symptoms are missed or dismissed. Recent reviews say that Parkinson’s epidemiology varies by race and ethnicity, but also warn that the literature is still heavily biased toward White and European-ancestry populations and is often not strong enough to separate biology from health-system inequality cleanly.

The clearest practical summary is this: in several large United States datasets, measured Parkinson’s prevalence has been highest in White groups, lower in Black groups, and also lower in Asian groups, while one classic California incidence study found Hispanics with the highest incidence and Black patients with the lowest. That tells us two important things at once. First, ethnicity-related differences are real in the data. Second, they are not identical across prevalence studies and incidence studies, which strongly suggests that survival, diagnosis, migration, access to care, and environmental exposures are all part of the story, not only genetics.

Why ethnicity differences are difficult to measure cleanly

Before looking at numbers, it helps to say one important thing plainly. “Ethnicity” is not a gene. It is a social and historical category that may overlap with ancestry, culture, migration history, language, diet, occupation, neighborhood exposures, and healthcare access. So when one study reports more Parkinson’s in one ethnic group than another, that result does not automatically mean one group is genetically destined for higher risk. A 2023 review on racial and ethnic disparities in Parkinson’s makes exactly this point, stressing that observed differences may reflect ancestral biology, environmental exposures, diagnostic bias, insurance access, geography, and research design limitations all at once.

That warning matters because underdiagnosis is not evenly distributed. The same review notes that in the only U.S. door-to-door population-based study, Black individuals were twice as likely to be previously undiagnosed with parkinsonism as White individuals. That means part of the “lower prevalence” in some groups may be a counting problem, not a true protection effect. If fewer people are diagnosed, the map will always look lighter than the disease burden really is.

What percentages have been reported in different ethnic groups?

There is no single perfect global table that gives one fixed percentage for every ethnic group worldwide. The best available evidence comes from particular countries and health systems, especially the United States.

One of the most cited large U.S. Medicare studies reported age-standardized Parkinson’s prevalence of 2,168.18 per 100,000 in White men, compared with 1,036.41 per 100,000 in Black individuals and 1,138.56 per 100,000 in Asian individuals. Converted into percentages, those figures are about 2.17%, 1.04%, and 1.14% respectively in that older Medicare population. Those numbers are not all-age population estimates. They come from a Medicare-age population and therefore look much higher than all-age percentages, because Parkinson’s becomes far more common in older adults.

A more recent 2023 disparities review summarizes the U.S. literature in a broader way rather than one exact table. It states that most studies report the greatest prevalence and incidence in White individuals, followed by Latino, Asian, Black, and Native American groups, with Native American groups usually showing the lowest reported rates in the available literature. That review also emphasizes that data for Latino, Asian, and Native American groups remain much thinner than data for White and Black populations, so the rank order should be treated as an informed pattern, not a universal law.

If we turn from prevalence to incidence, a classic Northern California study found age- and gender-adjusted Parkinson’s incidence rates of 16.6 per 100,000 in Hispanics, 13.6 in non-Hispanic Whites, 11.3 in Asians, and 10.2 in Blacks. In percentage terms, that is about 0.0166%, 0.0136%, 0.0113%, and 0.0102% per year. These are annual incidence rates, not prevalence, so they are much smaller numbers. But they are useful because they show a slightly different ordering from the Medicare prevalence study. Hispanics came out highest in this incidence dataset, which suggests that the ethnic story changes depending on the population, age structure, and method used.

So if someone asks for a simple working summary from U.S. data, it would be this:

• White populations often show the highest measured prevalence in large U.S. datasets.

• Hispanic populations sometimes show incidence rates similar to or higher than Whites in certain studies.

• Asian populations are often reported below Whites but above Black populations in some U.S. datasets.

• Black populations are frequently reported with lower measured prevalence and incidence, but underdiagnosis and delayed diagnosis are major concerns.

• Native American data remain sparse, and current conclusions are much weaker because the evidence base is thin.

Does this mean White populations are genetically more vulnerable?

Not necessarily, at least not in a simple one-line way.

There are real genetic findings in Parkinson’s that vary by ancestry. A 2024 genetics review states that up to 15% of Parkinson’s patients carry pathogenic variants in Parkinson’s-associated genes, and some ancestry-linked patterns are well established. For example, GBA1 variants are found in about 5% to 15% of all Parkinson’s cases, but can reach up to 20% in Ashkenazi Jewish populations. LRRK2 variants account for about 1% to 5% of all Parkinson’s cases, but can reach up to 15% in Ashkenazi Jews and 40% in North African Berbers. These are striking differences, and they clearly show that ancestry-linked genetic architecture matters for at least some subgroups.

The 2023 disparities review also notes that the common LRRK2 G2019S mutation is more frequent in people of Basque, Ashkenazi Jewish, and North African origin, while different LRRK2 variants may be more relevant in Latino and East Asian populations. That means genetics is absolutely part of the ethnic story. But genetics alone does not cleanly explain the full epidemiology of Parkinson’s across ethnic groups. If it did, the prevalence and incidence patterns would probably be more stable from one dataset to another than they actually are.

How much of the difference is environmental?

Quite possibly a lot.

Environmental exposures long associated with Parkinson’s include pesticides, rural well-water patterns, heavy metals, solvents, and some occupational exposures. A recent epidemiology review in The Lancet notes that Parkinson’s varies by geography, ethnicity, age, and sex, and that international increases are likely not explained by aging alone. Environmental influences remain one of the major suspected drivers.

The 2023 disparities review makes an especially important point here. It notes that Parkinson’s is more common among Black Americans than among Nigerians, and more common among men of Japanese or Okinawan descent living in the United States than among those living in Asia. That kind of contrast argues against a purely genetic explanation. If shared ancestry were the whole answer, moving across countries should not shift the rates so much. Differences like these strongly suggest that environment, migration, diet, urbanization, occupational exposures, healthcare access, or some mixture of all of them is shaping risk.

At the same time, environmental evidence by ethnicity is still frustratingly incomplete. Most studies do not report pesticide or rural-living data carefully by race and ethnicity. One small study cited in the disparities review even found that rural living, farming area exposure, and well-water use were associated with Parkinson’s in Black patients only within that small sample, but the authors and reviewers are clear that such data are too limited for firm conclusions. So the environmental side of the ethnicity puzzle is real, but still undermeasured.

How much of the difference is actually a healthcare access problem?

Probably more than many people assume.

The 2023 review stresses that medical-record-based and administrative-data studies may miss Parkinson’s in people who face language barriers, insurance problems, poorer primary care access, more comorbidity, or less access to neurology. It also notes that diagnosis may be missed or delayed in minoritized groups even when they show typical symptoms. That means “lower prevalence” in some populations can partly reflect weaker diagnostic capture rather than lower true disease burden.

This point has practical weight. A later 2025 commentary on race and ethnicity in Parkinson’s risk research argues that the field has done a poor job integrating race and ethnicity meaningfully, and that underrepresentation of non-White groups continues to limit how confidently we can interpret differences in prevalence and risk. In other words, some of the map is still blurry because the research lens has been pointed in one direction for too long.

So what contributes more, genetics or environment?

The fairest answer is that both contribute, but their balance changes depending on the subgroup and the question being asked.

For rare and monogenic Parkinson’s forms, genetics can be decisive. In certain ancestral communities, known variants such as LRRK2 or GBA1 contribute substantially and can strongly influence age at onset, phenotype, and family clustering.

For common later-life Parkinson’s across broad ethnic populations, the story looks more mixed. Genetics sets part of the stage, but environmental exposures, survival differences, access to diagnosis, healthcare quality, and research undercounting all appear to shape the final numbers we see. The 2023 disparities review explicitly says that major knowledge gaps remain about whether observed racial and ethnic differences reflect monogenic or polygenic risk, socially determined environmental exposures, receipt of unbiased care, or weaknesses in current research design. That sentence is really the heart of the matter.

So if you want the plain-language version: genetics loads some of the dice, environment decides part of the table, and healthcare systems decide who even gets counted in the game.

Why the ethnic differences should be interpreted carefully

There is a temptation to turn ethnicity findings into neat biological slogans. That would be a mistake.

A lower measured rate in one group does not automatically mean that group is biologically protected. It may partly mean shorter survival, more underdiagnosis, more missed referrals, or poorer access to movement-disorder specialists. Likewise, a higher measured rate in another group does not prove a purely genetic vulnerability. It may reflect better diagnosis, older average age, better survival with the disease, or more complete data capture.

This is why modern reviews keep returning to the same warning: Parkinson’s differences by ethnicity are real in the data, but the mechanisms are still only partly understood.

The bottom line

Parkinson’s prevalence does differ by ethnicity in many datasets, but the exact percentages depend heavily on age and study design. In a major U.S. Medicare study, age-standardized prevalence was reported at 2.17% in White men, compared with about 1.04% in Black individuals and 1.14% in Asian individuals within that older population. In a Northern California incidence study, annual Parkinson’s incidence was highest in Hispanics (0.0166%), followed by non-Hispanic Whites (0.0136%), Asians (0.0113%), and Blacks (0.0102%). These numbers should not be treated as universal worldwide percentages, but they do show meaningful ethnic variation in measured burden.

As for why the differences exist, the evidence supports a mixed explanation. Genetics clearly matters in certain populations, especially where ancestry-linked variants such as LRRK2 and GBA1 are more common. But environmental exposures, migration, occupational patterns, rural or urban living, diagnostic access, underrecognition, and health-system bias also appear to contribute substantially. The current research literature does not support reducing the answer to “only genes” or “only environment.” It is both, with healthcare access shaping the visibility of the disease on top of that.

FAQs: Parkinson’s, Ethnicity, Genetics, and Environment

1. Which ethnic group has the highest measured Parkinson’s prevalence in many U.S. studies?

Many U.S. studies report the highest measured prevalence in White populations, although some incidence studies have found Hispanics at the top.

2. What percentages have been reported for White, Black, and Asian groups?

In one large U.S. Medicare study of older adults, age-standardized prevalence was about 2.17% in White men, 1.04% in Black individuals, and 1.14% in Asian individuals. These are older-population figures, not all-age population percentages.

3. Are Hispanics affected more or less than Whites?

It depends on the dataset. In one Northern California incidence study, Hispanics had the highest annual incidence, slightly above non-Hispanic Whites.

4. Do lower measured rates in Black populations prove lower true risk?

No. Underdiagnosis and delayed diagnosis are major concerns, and one U.S. population-based study found Black individuals were twice as likely to be previously undiagnosed with parkinsonism as White individuals.

5. Do genetics clearly differ across ethnic groups?

Yes, for some variants. GBA1 and LRRK2 frequencies vary substantially by ancestry, with especially high frequencies in some Ashkenazi Jewish and North African groups.

6. Does that mean genetics explains most ethnic differences?

Not completely. Modern reviews say the observed differences likely reflect a mixture of genetics, environmental exposures, and healthcare access.

7. Can migration change Parkinson’s risk patterns?

Probably yes. Parkinson’s has been reported as more common in Black Americans than Nigerians, and more common in Japanese or Okinawan men living in the U.S. than in Asia, which points toward environmental and social influences.

8. Are environmental factors important?

Yes. Pesticides, heavy metals, solvents, and rural or occupational exposures remain important suspected contributors, although ethnicity-specific environmental data are still limited.

9. Why is it so hard to give one exact global percentage by ethnicity?

Because studies differ in age range, country, case definition, diagnostic access, and how race or ethnicity is recorded. Many groups are also underrepresented in Parkinson’s research.

10. What is the simplest way to understand ethnicity differences in Parkinson’s?

Ethnic differences in Parkinson’s are real in the statistics, but they are built from three layers at once: inherited risk, lived environment, and who gets seen clearly by the healthcare system.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more